v3.26.1
Sale of Manufacturing Facilities to Zydus (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
Jan. 15, 2026
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Disposal Group, Including Discontinued Operations [Line Items]            
Gain on Zydus asset sale   $ 0 $ 0 $ (40,379) $ 0  
Twelve-month escrow held   7,616   7,616   $ 0
Zydus agreements contract assets (Note R)   32,860   32,860   $ 0
Purchase Agreement [Member]            
Disposal Group, Including Discontinued Operations [Line Items]            
Gain on Zydus asset sale       (40,400)    
Purchased assets carrying value net $ 70,900          
Purchase Agreement [Member] | Zydus Lifesciences Ltd [Member]            
Disposal Group, Including Discontinued Operations [Line Items]            
Consideration allocated to sale of asset $ 8,800          
License Agreement [Member] | Zydus Pharmaceuticals Inc [Member]            
Disposal Group, Including Discontinued Operations [Line Items]            
Percentage of royalty on net sales in exchage for license 5.00%          
License agreement period 10 years          
Securities Purchase Agreement [Member] | Zydus Lifesciences Ltd [Member]            
Disposal Group, Including Discontinued Operations [Line Items]            
Cash consideration received $ 7,200          
Securities Purchase Agreement [Member] | Zynext Ventures USA LLC [Member]            
Disposal Group, Including Discontinued Operations [Line Items]            
Number of shares issued in transaction 2,133,333          
Consideration received in transaction $ 16,000          
Sale price per share $ 7.5          
Zydus Agreements [Member]            
Disposal Group, Including Discontinued Operations [Line Items]            
Zydus agreements contract assets (Note R)   40,000   40,000    
Payment recorded as reduction to contract asset       7,100    
Remaining right to clinical supply non-cash consideration   10,000   10,000    
Zydus Agreements [Member] | Zydus Lifesciences Ltd [Member]            
Disposal Group, Including Discontinued Operations [Line Items]            
Cash consideration received $ 91,000     91,000    
Transaction expenses 5,800     5,800    
Twelve-month escrow held 7,500          
Zydus Manufacturing Business [Member]            
Disposal Group, Including Discontinued Operations [Line Items]            
Required usage amount to trigger first payment       20,000    
Purchased Assets [Member] | Purchase Agreement [Member]            
Disposal Group, Including Discontinued Operations [Line Items]            
Total consideration 111,300          
Purchased Assets [Member] | Purchase Agreement [Member] | Zydus Pharmaceuticals Inc [Member]            
Disposal Group, Including Discontinued Operations [Line Items]            
Asset purchase, contingent consideration amount 50,000          
Non-cash contingent service consideration 50,000          
Estimated first potential payment received as consideration   20,000   20,000    
Estimated second potential payment received as consideration   20,000   20,000    
Estimated aggregate of two potential payment received as consideration   40,000   40,000    
Non-cash consideration excluded from transaction price   $ 10,000   $ 10,000    
Purchased Assets [Member] | Zydus Agreements [Member] | Zydus Lifesciences Ltd [Member]            
Disposal Group, Including Discontinued Operations [Line Items]            
Cash consideration received $ 71,400